Drug ProductApprovals (Licensed) Granted from the Department of Health, ROC
After completing the formulation studies and/or bioavailability studies (these were performed and funded during the period of Directorship of the Department of Research and Development, Kingdom Pharmaceutical Co., which has been the Teaching Pharmaceutical Plant of the National Defense Medical Center.), the following products have been marketed in Taiwan:
72 hrs’ Epirubicine plasma concertation after administering adjusted dose(75~110 mg/m2) among 38 Nasopharyngeal Carcinoma patients
: 77-96, 1992.
Time (month)
After 6 years follow-up, complete responder’s survival rate are highly significant higher than partial responder and non-responder, (Breslow-test, p=0.037)
Science, 13(2) : 77-96, 1992.
The Mechanism of Reducing Thiopentone Dose in Elderly Patients undergoing Surgery
Shung-Tai Ho＊, Oliver Y. P. Hu
Weber Ho
, Li-Heng Pao
and Shin-Chun Lee
Department ofAnesthesiology, National Defense Medical Center
School of Pharmacy, National Defense Medical Center
Department ofAnesthesiology, Far Eastern Memorial Hospital
Department of Surgery, National Defense Medical Center
Taipei, Taiwan Republic of China
新藥研發的專業與查登機制的建立 發明unmet medical need
寶塔式的研發成果
Strategies for New Drug, New Diagnostic Kits Development and Its Applications in Taiwan
(Policy)
(Strategy)
(Tactics)
用世界的難題 吸引世界級的人才
What’s the Problems for Pain Control
Especially Moderate to Severe Pain :
1. Almost all the pain killer for moderate to severe pain are:
(1) Narcotics with addiction
(2) Respiratory suppression may cause death
(3) possible vasodialation
(4) Reduce GI motility
(5) Convulsant effects
2. Not a moderate to severe (M/S) pain killer for post operation pain has a duration longer than one day.
Pharmacokinetic Basis of Novel
Drug Design and Development
Topic Selection
Thousands of Diseases
Just Several Kinds of Pain
Development of Non–addiction, Non–respiratory Depression,
Once a Week, NovelAnalgesic for Severe Pain
Prof. Oliver Yoa-Pu Hu, Ph. D., FNAI (USA), FAAPS (USA)
Shung-Tai
Ho,
Deputy Superintendent
Cheng-Huei Hsiong, Ph.D.
Opioid Receptor Major Subtypes (I)
Receptor Subtypes Location Function
mu (μ)
μ1, μ2, μ3
brain
spinal cord
peripheral
intestinal tract
μ1: analgesia
physical dependence
μ2: respiratory depression euphoria reduced GI motility physical dependence
μ3:
possible
Opioid Receptor Major Subtypes (II)
Receptor Subtypes Location Function kappa (κ) κ1, κ2, κ3
brain
spinal cord
peripheral
analgesia
anticonvulsant effects
depression
dissociative/hallucinogenic effects
sedation
Cell Volume 172, Issues 1-2, p55–67.e15, 11 January 2018
Polynalbuphine Ester
Note : Thanks for the support from National Science Council (NT$8,300萬)
Drug Design : Multiple Warhead Missile
The original missile design has a single warhead inside the nose cone. The new model has multiple warheads that can be aimed independently.
An Innovative Cold Tail-Flick Test: Cold Ethanol Tail-Flick Test Kappa Receptor Efficacy Study
Abstract
An innovative antinociceptive test, the cold ethanol tail-flick test (CET), was developed for evaluating the actions of opioid analgesics. To select an optimal operation temperature range for the CET, temperatures from -5 degrees C to -30 degrees C were screened. After screening, temperatures ranging between -20 degrees C and -30 degrees C were both strong and effective enough to act as a noxious cold stimulus. In the following study, -20 degrees C was selected as the cold stimulus for the CET. The sensitivity and specificity of this test were challenged by opioid analgesics: an agonist (morphine) and two agonist-antagonists (buprenorphine and nalbuphine), two tranquilizers (droperidol and diazepam), and four nonopioid analgesics (acetaminophen, aspirin, indomethacin, and ketoprofen). The sensitivity of the CET was also compared with the assays using heat (radiant heat and hot water). The AD50 values determined by the CET for morphine, buprenorphine, and nalbuphine were 0.16 mg/kg, 0.22 micrograms/kg, and 0.19 mg/kg, respectively. Naloxone, an opioid antagonist, blocked the antinociceptive effects of these opioids which were determined by the CET. Furthermore, the tranquilizers and nonopioid analgesics did not show any activity in the CET. Our results show that not only can the CET assess the antinociceptive activity of both opioid agonist and mixed agonist-antagonist, it also possess the characteristics of sensitivity, specificity, simplicity, and reproducibility.
(Formulation Studies)
Note : Thanks for the support from National Science Council (NT$8,300萬)
Nalbuphine in Beagle Dogs After IM 5 mg/kg of Nalbuphine-HCl or 30 mg/kg of SDE
to Assess the Safety, Tolerability and Pharmacokinetics of SDE
Nalbuphine in Healthy Subjects After IM 17 mg of NH or 75, 100mg, 125 mg of SDE (II)
SDE 150mg(Taiwan)
SDE 125mg (Taiwan)
SDE 100mg (Taiwan)
SDE 75mg (Taiwan)
Nalbuphine-HCl 17mg (Taiwan)
8 hrs postNH injection
AUCinf of NH of Healthy Subjects after IM SDE
Phase II / III Clinical Trial
A Randomized, Double Blind, Placebocontrolled, Single Dose Study to Assess the Safety and Efficacy of Intramuscular
SDE For Post-hemorrhoidectomy Pain Management
Study Procedure
Population：220 Hemorrhoid subjects
(已排定要進行2或3處切除之痔瘡手術者)
SDE/placebo single dose
Chemistry/Hematology
Screening
Confirm Eligible, Arrange Surgery
需住院，Day 3出院
Injection site evaluation Vital signs evaluation
Primary Endpoint: VAS Assessment before the first use of PCA Ketorolac, and at 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 h after the surgery
Nalbuphine concentration of
subjects in SDE Phase I and Phase II / III study
(Phase II/III/Taiwan)
(Phase I/Taiwan)
Primary Endpoint -
AUC0-48 of VAS Scores During 48 Hours After Hemorrhoid Operation
0-48 Data = Mean SD
1ANOVAwith treatment *Significant at 5% level
Secondary Endpoint 1 -
Amount of Ketorolac (mg) Administered by PCA Through 48 Hours After Hemorrhoid Operation
PCAconsumption Data = Mean SD
1ANOVAwith log-transformation of PCAconsumption of treatment
2Number of observation
*Significant at 5% level
Discussions – SDE’s AE Compare with Morphine’s AE
Indication
the relief of moderate to severe acute and chronic pain
Gastrointestinal AE
Nervous system and general AE
Common (1% to 10%): Dry mouth, constipation, nausea, diarrhea, anorexia, abdominal pain, vomiting
the relief of moderate to severe acute and chronic pain
Vomiting (2.8%), nausea (1.8%)
Other common
AE (1% to 10%)
Very common (10% or more): Drowsiness (28%)
Common (1% to 10%): Dizziness, sedation, fever, anxiety, confusion, tremor, diaphoresis, lethargy, feeling of warmth Fever (16.5%), dizziness (6.4%)
Respiratory depression, Chest pain, Anemia, leukopenia, Rash, Peripheral edema No
Project Achievement
• Patents – 6 patents in 6 countries
– Long Acting Analgesic Nalbuphine Polyester Derivative and Method of Use. ROC Patent: 118461, 2000.
– Long Acting Analgesic Nalbuphine Polyester Derivative and Method of Use. U.S. Patent: 6,225,321, 2001.
– Long Acting Analgesic Nalbuphine Polyester Derivative and Method of Use. European Patent:1149836, 2003.
– Long analgesic acting nalbuphine polyester derivative and method of use. China Patent: ZL00108255.8, 2005.
– Long analgesic acting nalbuphine polyester derivative and method of use. Japan Patent: 4024992, 2007.
– Long analgesic acting nalbuphine polyester derivative and method of use. Korea Patent: 0534917, 2005.
• Published paper
- The Effect of Aging on the Pharmacokinetics of Nalbuphine in Rabbits. Biopharmaceutics and Drug Disposition, 16 : 695-703, 1995.
- Determination of Nalbuphine by High-performance Liquid Chromatography with Ultraviolet Detection : Application to Human and Rabbit Pharmacokinetic Studies. Journal of Chromatography B, 678 :289-296, 1996.
- Controlled Release of Nalbuphine Prodrug from Biodegradable Polymeric Matrices: Influence of Prodrug Hydrophilicity and Polymer Composition. International Journal of Pharmaceutics, 172: 1725 1998.
- Mucoadhesive Buccal Disks for Novel Nalbuphine Pro-drug Controlled Delivery: Effect of Formulation Variables on Drug Release and Mucoadhesive Performance. International Journal of Pharmaceutics., 177: 201-209 ,1999.
- High-performance method for the Simultaneous Determination of Nalbuphine and its Pro-drug, Sebacoyl Dinalbuphine Ester, in Dog Plasma and Application to Phamacokinetic Studies in Dogs. Journal of Chromatography 746 :241-247, 2000.
- Delivery of Nalbuphine and its Pro-drugs Across Skins by Passive Diffusion and Iontophoresis. Journal of Controlled Release. 1-8, 2000.
- Controlled Release of Nalbuphine Propionate from Biodegradable Microspheres: in vitro and in vivo studies. International Journal of Pharmaceuties 220 : 91-99,2002.
- Transdermal Delivery of Nalbuphine and Nalbuphine Pivalate from Hydrogels by Passive Diffusion and Iontophoresis. Arzneimittel-Forshung Drug Reserch 51:408-413, 2002.
Project Achievement
• Published paper
- The analgesic effect of nalbuphine and its long-acting pro-drug, nalbuphine arachidicate, in rats.
Formos J Surg 35:283-289, 2002
- The Analgesic Effect of Nalbuphine and Its Long-acting Pro-drug, Nalbuphine Pivalate, in Rats. Acta Anaesthesiol Sin 40: 191-195, 2002.
- The Selection of Oil for the Preparation of Long-acting Nalbuphine. Chin J Pain 13(1): 18-22, 2003
- The Analgesic Effect of Nalbuphine and Its Pro-drug, Nalbuphine Benzoate, in Rats, Chin J Pain 13(1):11-17, 2003
- The Method for Synthesizing Nalbuphine Esters. Chin J Pain 13(1):23-28, 2003
- Biodegradable Polymeric Microspheres for Nalbuphine Pro-drug Controlled Delivery: in Vitro Characterization and in Vivo Pharmacokinetic Studies. International Journal of Pharmaceutics. 7441:1-9, 2003.
- The Antinociceptive Effect of Nalbuphine and Its Long-Acting Esters in Rats. Anesth Analg, 97:806809, 2003.
- The Antinociceptive Effect of a Long-acting Nalbuphine Preparation in Rabbits. Acta Anaesthesiol Sin, 41:99-103, 2003.
- Antinociceptive Effect of a Novel Long-Acting Nalbuphine Preparation. British Journal of Anaesthesia 92 (5): 712-715, 2004.
- In Vitro and In Vivo Evaluation of the Metabolism and Pharmacokinetics of Sebacoyl Dinalbuphine. Drug Metabolism and Disposition, 33(3): 395- 402, 2005.
- The effects of electrically assisted methods on transdermal delivery of nalbuphine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels. International Journal of Pharmaceuics. 297(1-2):162-171, 2005.
- Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. Journal of Controlled Release 115:140-149,2006.
- Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in humans. Biomedical Chromatography. 27：831-837,2013.
Development of Diagnostic Kit for Residual Liver Function – GSP Method
Prof. Oliver Yoa-Pu Hu, Ph. D., FNAI (USA), FAAPS (USA)
Deputy Superintendent
Comparison of Various Quantitative Liver Function Tests
Method Advantages
Child-Pugh Simple, convenient, semi- quantitative
Disadvantages
Qualitative. The Child-Pugh classification uses factors such as ascites and encephalopathy to evaluate liver function; therefore, it is mainly used to assess severe dysfunction.
2. Quantitative, blood flow and enzyme activity, not affected by CYP or conjugated metabolic system
3. Use strip to rapid detect QLFT, Point-ofCare
4. Galactose is a natural and safe compound
5. The GSPand OGSPtests appeared to be more appropriate than the Child-Pugh and MELD scores for patients with liver dysfunction across the entire normal-to-severe spectrum.
3 min i.v. Bolus, fasting.
Galactose Metabolized in Liver Becomes Glucose-1-Phosphate Then
Produced ATP, Not Glucose (Diabetes Mellitus Patient Can Use)
Galactose
90% galactose metabolized in the liver
1. Galactose is extensively metabolized by liver - reflect the CLint
2. Galactose is highly extracted by liver – reflect the QH, hepatic blood flow. When not saturated.
3. When galactose saturated, the clearance will reflect the hepatic enzymes activities.
CLint reflect the hepatic enzymes activities QH reflect the hepatic flow
pathway
Hepatic Clearance Correlated with Hepatic Blood Flow and Enzymes Activities
• Galactose is extensively metabolized by liver - reflect the CLint
• Galactose is highly extracted by liver – reflect the QH
CLint reflect the hepatic enzymes activities QH reflect the hepatic flow
Assessment of Liver Function Using a Novel Galactose Single Point Method
Tang HS and Hu OYP, Digestion 1992;52:222-231
Fig.2. The galactose saturation time period in normal volunteers (a) and patients with cirrhosis (b) obtained from each person’s galactose concentration time curve after receiving quick intravenous administration of 0.5 g/kg galactose.
Fig2. The galactose saturstion time period in normal volunteers (a) and
Fig.3. Difference of galactose blood concentration at different time point between 51 normal healthy volunteers and 36 patients with cirrhosis after 0.5 g/kg galactose was infused intravenously for 3 min. The concentration 40, 50 and 60 min after infusion give highly significant difference between these two groups.
Point of Care, Clinically Useful Galactose Single Point (GSP) and Oral GSP (OGSP) Method
• Oral 0.5g/kg or i.v. infused (3~5min.) of galactose, and measuring whole blood galactose concentration at 60 minutes.
Point of Care, Clinically Useful Galactose Single
Point
(GSP) and Oral GSP (OGSP) Method
Galactose Monitoring System Can Rapid Detect Quantitative Liver Function ( QLF )
GSP Method Has Been Recommended by U.S. FDA
Guidance for Industry
Pharmacokinetics in Patients with Impaired Hepatic Function: Study
Design, DataAnalysis, and Impact on Dosing and Labeling
U.S. Department of Health and Human Services
Food and DrugAdministration
Center for Drug Evaluation and Research (CDER)
Center for Biologics Evaluation and Research (CBER)
May 2003
Clinical Pharmacology
半乳糖單點法測定人肝臟剩餘功能
Assessment of Liver Function Using a Novel Galactose Single Point (GSP) Method
Guidance for Industry, Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, DataAnalysis, and Impact on Dosing and Labeling U.S. FDAMay 2003
肝功能不全病患的藥動學試驗基準
－臨床試驗設計、數據分析以及對劑量調整與標示的影響
Tang HS and Hu OYP, Digestion 1992; 52(3): 222-231
肝功能不全病患的藥動學試驗基準
－臨床試驗設計、數據分析以及對劑量 調整與標示的影響
肝功能評估-推薦方法之一
2、半乳糖單點法（Galactose Single Point, GSP） 本法乃是由唐鴻舜及胡幼圃發表於1992年之Digestion期刊中。GSP為於空腹時， 三分鐘快速靜脈輸注0.5 g/kg的半乳糖，經過60分鐘後，測量受試者血中半乳糖的
Capacity Predicts Complications and Survival After Hepatic Resection
Ann Surg 2002; 235(1): 77-85
Published GSP Application Papers (I)
1. Hung-Shang Tang and Oliver Yoa-Pu Hu. Assessment of Liver Function Using a Novel Galactose Single Point Method. Digestion 1992; 52: 222-231.
2. Oliver Yoa-Pu Hu, Hung-Shang Tang and Ching-Ling Chang. The Influence of Chronic Lobular Hepatitis on Pharmacokinetics of Cefoperazone -A Novel Galactose Single-Point Method as A Measure of Residual Liver Function. Biopharmaceutics and Drug Disposition 1994; 15: 563-576.
3. Oliver Yoa-Pu Hu, Teh-Min Hu and Hung-Shang Tang. Determination of Galactose in Human Blood by High-Performance Liquid Chromatography: Comparison with Enzymatic Method and Application to the Pharmacokinetic Study of Galactose in Patients with Liver Dysfunction. Journal of Pharmaceutical Sciences 1995; 84(2): 231-235.
4. Oliver Yoa-Pu Hu, Hung-Shang Tang, Tuzen-Yen Sheeng, Tung-Chao Chen and Stephen H. Curry. Pharmacokinetics of Promazine in Patients with Hepatic Cirrhosis–Correlation with a Novel Galactose Single Point Method. Journal of Pharmaceutical Sciences 1995; 84(1): 111-114.
5. Oliver Yoa-Pu Hu, Hung-Shang Tang and Ching-Ling Chang. Novel Galactose Single Point Method as a Measure of Residual Liver Function: Example of Cefoperazone Kinetics in Patients with Liver Cirrhosis. Journal of Clinical Pharmacology 1995; 35: 250-258.
6. Hung-Shang Tang, Oliver Yoa-Pu Hu, Feng-Chen Wu, Ton-Ho Young, Teh-Min Hu and You-Chen Chao. Prognostic Value of Galactose Elimination Capacity in Patients with Cirrhosis Based on a Serial Determination. Journal Med Sciences 1996; 16(5): 295 -305.
7. Hung-Shang Tang, Oliver Yoa-Pu Hu, You-Chen Chao, Ton-Ho Young and Teh-Min Hu. The Clinical Significance of Assay Serum Collagen IV 7S Collagen in Patients with Hepatitis B-Related Liver Disease. Journal Med Sciences 1998; 18(5): 306-315.
8. Ton-Ho Young, Hung-Shang Tang, Herng-Sheng Lee, Cheng-Huei Hsiong and Oliver Yoa-Pu Hu. Effects of Hyperglycemia on Quantitative Liver Functions by the Galactose Load Test in Diabetic Rats. Metabolism Clinical and Experimental 2007; 56: 1265-1269.
9. Ton-Ho Young, Hung-Shang Tang, You-Chen Chao, Herng-Sheng Lee, Cheng-Huei Hsiong, Li-Heng Pao and Oliver YoaPu Hu. Quantitative Rat Liver Function Test by Galactose Single Point Method. Laboratory Animals 2008; 42: 495-504.
10. Chung-Jung Lin, Ming-Fang Yen, Oliver Yoa-Pu Hu, Min-Shung Lin, Cheng-Huei Hsiong, Chin-Chuan Hung and HorngHuei Liou. Association of Galactose Single-Point Test Levels and Phenytoin Metabolic Polymorphisms with Gingival Hyperplasia in Patients Receiving Long-Term Phenytoin Therapy. Pharmacotherapy 2008; 28(1): 35-41.
Published GSP Application Papers (II)
11. Jr-Ting Lee, Li-Heng Pao, Meei-Shyuan Lee, Jiunn-Wang Liao, Chi-Min Shih, Cheng- Huei Hsiong, Fon-Yi Yin, TungYuan Shih and Oliver Yoa-Pu Hu. A New Approach to Facilitate Diagnosis of Nonalcoholic Fatty Liver Disease Through a Galactose Single Point Method. Digestive and Liver Disease 2013; 45: 134-141.
12. Tung-Yuan Shih, Chien-Yi Pai, Ping Yang, Wen-Liang Chang, Ning-Chi Wang and Oliver Yoa-Pu Hu. A Novel Mechanism Underlies the Hepatotoxicity of Pyrazinamide. Antimicrobial Agents and Chemotherapy 2013;57(4):16851690.
13. Tung-Yuan Shih, Ton-Ho Young, Herng-Sheng Lee, Chung-Bao Hsieh and Oliver Yoa-Pu Hu. Protective Effect of Kaempferol on Isoniazid and Rifampicin-Induced Hepatotoxicity. AAPS J 2013; 15(3): 753-762.
14. Tung-Yuan Shih, Shan-Chu Ho, Cheng-Huei Hsiong, Tien-Yu Huang and Oliver Yoa-Pu Hu. Selected Pharmaceutical Excipient Prevent Isoniazid and Rifampicin Induced Hepatotoxicity. Curr Drug Metab 2013; 14(6)：720-728.
15. Yi-Chou Hou, Wen-Chih Liu, Min-Tser Liao, Kuo-Cheng Lu, Lan Lo, Heng-Chih Pan, Chia-Chao Wu, Oliver Yoa-Pu Hu and Hung-Shang Tang. Long-Term and Short-Term Effects of Hemodialysis on Liver Function Evaluated Using the Galactose Single-Point Test. Scientific World Journal 2014; 2014: 260939.
16. Kuo-Ming Yu, Ping Yang, Tien-Yu Huang, Thomas Yen-Shih Shen, Johnson Yiu-Nam Lau, Oliver Yoa-Pu Hu. A Novel Galactose Electrochemical Biosensor Intended for Point-of-Care Measurement of Quantitative Liver Function Using Galactose Single-Point Test. Anal Bioanal Chem 2022 ;414(14): 4067-4077.
17. Tung-Yuan Shih, Ton-Ho Young, Tien-Yu Huang, Hong-Shun Tang, Hsin-Tien Ho, Ping Yang, Johnson Yiu-Nam Lau and Oliver Yoa-Pu Hu. Galactose Single Point Method as a Safe, Simple, High-Sensitive Quantitative Liver Function Assessment in Patients with Non-alcoholic Fatty Liver Disease. GUT 2024. (submitted)
18. Tung-Yuan Shih, Wan-Ling Yang, Pei-Wei Huang, Cheng-Huei Hsiong, Te-Yu Lin, Kai-Min Chu, Oliver Yoa-Pu Hu. Pain Relief with a Novel Acetaminophen Formulation Without Fear of Hepatotoxicity. Hepatology 2024. (submitted)
19. Tien-Yu Huang, Hsuan-Hwai Lin, Ping Yang, Kuo-Ming Yu, Johnson Yiu-Nam Lau and Oliver Yoa-Pu Hu. Quantitative Measurement of Liver Dysfunction by an Oral Point-of-Care Galactose Single-Point Method. Journal of Gastroenterology 2024. (submitted)
Table1. Top-50 Selling Drugs from the 2017 Data (Drugs
Avoid or Withhold )-1
2. Opdivo Nivolu mab Opdivo is not extensively metabolize d in the liver. Oncology 4,948
“Warnings and precautions” and “contraindications” for any liver impairment
Immune-mediated hepatitis: Monitor for changes in liver function. Withhold for moderate and permanently discontinue for severe or life-threatening transaminase or total bilirubin elevation.
Dose modification
Use in Patients with Hepatic Impairment
CYP3A5 和
CYP2J2 代
• Avoid the use of XARELTO in patients with moderate and severe hepatic impairment or with any hepatic disease associated with coagulopathy. Hepatic impairment:
• Avoid use in patients with moderate and severe hepatic impairment or with any degree of hepatic disease associated with coagulopathy.
Hepatic Impairment
Crestor is contraindicated in patients with active liver disease.
Chronic alcohol liver disease ; Crestor should be used with caution in these patients.
Rosuva statin
2. Valproic acid (Depakene)
5. Phenytoin Phenytoin is primarily metabolized by the liver, specifically by the enzyme CYP2C9
Mild to moderate impairment: Not recommended for use in hepatic disease
Has liver disease, the dose of phenytoin may need to be adjusted to avoid potential toxicity or insufficient therapeutic effects.
Table1. Summary of DrugAvoid in Cirrhosis-4
New drug to treat NASH: SNP-6 MASH
Pathogenesis of fatty liver disease
High fat diet, metabolic syndrome
Comparison of the Efficacy of oral SNP-6 and the front runner - Elafibranor (Genfit)*
Fig. Changes from baseline in ALT in treatment groups. Results are expressed in mean values of changes from baseline during treatment with placebo (n=77), elafibranor 80 mg (n=82), elafibranor 120 mg (n=78) and SNP-6 (n=17). Error bars represent 95% CIs. ALT, alanine aminotransferase. *Elafibranor data is adapted from the GOLDEN-505 trial published in Gastroenterology 2016;150:1147–1159
Liver Disease Research (Basic R&D Team)
博士
Hsin-Tien Ho, Ph.D.
Postdoc, National Defense Medical Center, Taiwan
Ph.D., Graduate institute of Life Sciences, National Defense Medical Center, Taiwan
Shin-Wei Chen, Ph.D.
CTO, I Care You Biotech, Taiwan
Ph.D., Graduate School of Science, The University of Tokyo, Japan
Chang-Hui Tsao, Ph.D.
Postdoc, VIB-KU Leuven Center for Brain & Disease Research, Belgium
Ph.D., Graduate institute of Life Sciences, National Defense Medical Center, Taiwan
Ph.D., The Institute of Basic Medical Sciences, National Cheng Kung University, Taiwan 陳欣蔚 博士
Yuan-Chang Hsu, Ph.D.
Pharm/Tox Reviewer
Division of New Drugs, Center for Drug Evaluation, Taiwan
Liver Disease Research (Clinical Team)
施宇隆
Yu-Lueng Shih, MD, Ph.D.
1. Associate professor
2. Attending Physician, Division of Gastroenterology
Tien-Yu Huang, MD, Ph.D.
1. Associate professor
2. Attending Physician, Division of Gastroenterology
3. Superintendent of the Tri-Service General Hospital Penghu Branch 林榮鈞
Chang-Hsien Liu, MD
1. Director of the Radiological Diagnosis Department
2. Assistant professor
3. Director of the Endoscopy center
2. Associate professor 黃天佑
Wen-Hui Fang, MD
1. Director of the Family and Community Health Department and International Medical Service Center
Jung-Chun Lin, MD, Ph.D.
1. Attending Physician, Division of Gastroenterology
2. Assistant professor
Te-Yu Lin, MD
Attending Physician, Division of Infectious Diseases and Tropical Medicine
Chih-Weim Hsiang, MD
Attending Physician, Department of Radiology
Pain Control Research (Clinical Team)
Wei-Ming Chen, MD, Ph.D.
1. Superintendent of Taipei Veterans
General Hospital, Taiwan
2. Professor of Orthopaedics
3. President Elect Asia Pacific
Musculoskeletal Tumour Society
Yu-Kuan Lin, MD
1. Division of Joint Reconstruction
2. Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taiwan
Cheng-Fong Chen, M.D., Ph.D.
1. Division of Joint Reconstruction
2. Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taiwan
3. Associate professor
Yung-Chih Wang, MD
1.Attending Physician
2. Division of Infectious Diseases and Tropical Medicine, Tri-Service General Hospital, Taipei, Taiwan.
3.Associate professor
Chun-Sung Sung, MD, Ph.D.
1. Attending Physician and Director of Pain Management, Department of Anesthesiology, Taipei Veterans General Hospital, Taiwan
2. Associate professor
Te-Yu Lin, MD
1.Attending Physician
2. Division of Infectious Diseases and Tropical Medicine, Tri-Service General Hospital, Taipei, Taiwan.
3.Associate professor
Shang-WenTsai, MD
1. Division of Joint Reconstruction
2. Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, Taiwan
Pain Research (Clinical Team)
王永志 醫師
Yung-Chih Wang, MD, Ph.D.
1.Associate professor
吳明玲 醫師
Hsien-Hao Huang, MD, Ph.D.
1.Assistant Professor
2.Attending Physician, Division of Infectious Diseases and Tropical Medicine 黃獻皞 醫師
2.Attending doctor, Department of Emergency Medicine, Taipei Veterans General Hospital
Ming-Ling Wu, MD, Ph.D.
Attending Physician, Department of Occupational Medicine and Clinical Toxicology, Taipei Veterans General Hospital
Teh-Fu Hsu, MD.
1.Attending Physician
2.Assistant professor, School of Medicine, National YangMing University
